Histological assessment of a novel restorative coronary artery bypass graft in a chronic ovine model.

IF 4.3 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Frontiers in Bioengineering and Biotechnology Pub Date : 2025-02-10 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1488794

Yu Sato, Matthew Kutnya, Biniyam Abebe, Mohammed S El Kurdi, Martijn Cox, Richard W Bianco, Bart Meuris, Yoshinobu Onuma, Patrick W Serruys, Renu Virmani

{"title":"Histological assessment of a novel restorative coronary artery bypass graft in a chronic ovine model.","authors":"Yu Sato, Matthew Kutnya, Biniyam Abebe, Mohammed S El Kurdi, Martijn Cox, Richard W Bianco, Bart Meuris, Yoshinobu Onuma, Patrick W Serruys, Renu Virmani","doi":"10.3389/fbioe.2025.1488794","DOIUrl":null,"url":null,"abstract":"Background: Although prosthetic conduits for coronary artery bypass grafting (CABG) are increasingly needed because of the limited availability and patency of autologous conduits, no alternatives have succeeded.Methods: Sixteen sheep underwent CABG. Thirteen received a bioabsorbable polymer graft with an incorporated nitinol microskeleton (Xeltis coronary artery bypass graft [XABG]), and three received autologous saphenous vein grafts (SVG). Pathological evaluation was conducted at 12 months.Results: In the XABG group, two sheep died perioperatively; two were sacrificed at 3 months (1 occluded, 1 patent) and two at 6 months (both patent). Two more died from occlusion at 9-10 months, and five survived with patent grafts at 12 months. All SVGs remained patent for 12 months. Histology demonstrated near-complete luminal endothelialization in XABG, with increased polymer adsorption and matrix deposition. The cross-sectional area of the SVG lumen was significantly larger than XABGs (48.2 mm2 vs 12.9 mm2, p = 0.0018), consistent with a reduced angiographic flow velocity in SVG. The neointimal area was greater in SVGs than XABGs (19.6 vs. 6.7 mm2, p = 0.0005), especially at the distal ends of SVGs due to thrombus formation.Conclusion: XABG demonstrated 1-year feasibility with consistent endothelialization and polymer absorption. While SVGs had better patency, they showed greater diametrical irregularity and subsequent neointimal proliferation.","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1488794"},"PeriodicalIF":4.3000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11847836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1488794","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Although prosthetic conduits for coronary artery bypass grafting (CABG) are increasingly needed because of the limited availability and patency of autologous conduits, no alternatives have succeeded.

Methods: Sixteen sheep underwent CABG. Thirteen received a bioabsorbable polymer graft with an incorporated nitinol microskeleton (Xeltis coronary artery bypass graft [XABG]), and three received autologous saphenous vein grafts (SVG). Pathological evaluation was conducted at 12 months.

Results: In the XABG group, two sheep died perioperatively; two were sacrificed at 3 months (1 occluded, 1 patent) and two at 6 months (both patent). Two more died from occlusion at 9-10 months, and five survived with patent grafts at 12 months. All SVGs remained patent for 12 months. Histology demonstrated near-complete luminal endothelialization in XABG, with increased polymer adsorption and matrix deposition. The cross-sectional area of the SVG lumen was significantly larger than XABGs (48.2 mm² vs 12.9 mm², p = 0.0018), consistent with a reduced angiographic flow velocity in SVG. The neointimal area was greater in SVGs than XABGs (19.6 vs. 6.7 mm², p = 0.0005), especially at the distal ends of SVGs due to thrombus formation.

Conclusion: XABG demonstrated 1-year feasibility with consistent endothelialization and polymer absorption. While SVGs had better patency, they showed greater diametrical irregularity and subsequent neointimal proliferation.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.